Amgen's ovarian cancer drug trials disappoint

November 5, 2014 2:45 AM

6 0

Ovarian cancer drug fails to improve overall survival rate in clinical trial. Amgen announces results of late-stage trial of drug trebananib(Photo : NIH)

In a late-stage trial of an ovarian cancer drug known as trebananib, it failed to result in significantly improved patient survival, the drug's maker Amgen, Inc., has reported.

Also read: Intel reports better-than-expected earnings as data center chips grow 13% to $4.5 billion

Read more

To category page